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Summary 
Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID), which, in animal tests, displays a high potency for 
anti-inflammatory and analgesic action. The aim of this study was to investigate the efficacy and tolerability of 15 mg 
meloxicam in comparison with 100 mg slow-release diclofenac in patients with osteoarthritis of the knee. Two hundred 
and fifty-eight patients were included in the intent-to-treat nalysis; these were randomized into two groups to receive 
either 15 mg meloxicam (N= 128) or 100 mg diclofenac (N= 130) for a period of 6 weeks. The results with respect o 
efficacy showed a trend in favor of meloxicam regarding pain on movement, global efficacy and paracetamol 
consumption, although these differences did not reach statistical significance. The most frequently-occurring adverse 
events in both groups were of a gastrointestinal (GI) nature. However, there was a higher incidence (26 vs 16%) of 
GI adverse vents in the diclofenac group compared with the meloxicam group. Both drugs were well tolerated when 
assessed by the patients on a visual analog scale (VAS). Thus, 15 mg meloxicam is an effective and well-tolerated 
therapy for osteoarthritis and compares favorably with diclofenac 100 mg, a well-established treatment for this 
indication. 
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Introduction 
OSTEOARTHRITIS is an  extremely  common con- 
dition. Most  people classif ied as disabled f rom 
arthr i t is  are considered to have osteoarthr i t i s  [1]. 
The knee jo int  is the most  common site of the 
disease, and the main  symptoms are pain, stiffness 
and loss of movement .  The pain  often becomes 
worse on use of the joint, leading to a loss of 
mobi l i ty  in the pat ient.  The condit ion is genera l ly  
managed by nonstero idat  ant i - in f lammatory  drugs 
(NSAIDs), which ease pain  and improve function. 
A l imitat ion of the NSAIDs is that  s ignif icant 
numbers  of pat ients  exper ience some form of 
gast ro intest ina l  (GI) discomfort.  This ranges from 
simple into lerance to major  and l i fe-threatening 
per format ions  and hemorrhages  [2, 3]. Clearly, if a 
NSAID combin ing eff icacy with a reduced inci- 
dence of adverse events could be produced, such an 
agent  would provide impor tant  pat ient  benefits 
and have  a centra l  role in the t reatment  of 
arthr it is .  
Me lox icam is a recent ly-developed NSAID, 
which is, an enolcarboximide der ivat ive with a 
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termina l  T½ of 20 h [4]. This al lows once  dai ly 
dosing with meloxicam, with a low r isk of 
accumulat ion  of the drug in body compartments .  
Me lox icam is an inh ib i tor  of in vitro and in vivo 
prostag land in  b iosynthes is  [5] and it is a preferen-  
t ial inh ib i tor  of in f lammatory  cyclo-oxygenase-2 
(COX-2) over  phys io logica l  cyclo-oxygenase-1 
(COX-l) [6], which is l ikely to resul t  in an improved 
GI  to lerabi l i ty  profile. 
Slow re lease (SR) dic lofenac in a dai ly dose of 
100 mg is establ ished in the t reatment  of pat ients  
with osteoarthr i t is .  The eff icacy of d ic lofenac in 
pat ients  with osteoarthr i t i s  is comparab le  with 
that  of indomethac in ,  naproxen,  ibuprofen, sulin- 
dac and diflunisal, and it is one of the bet ter  
to lerated NSAIDs [7-10]. 
This l~aper eports  the eff icacy and to lerab i l i ty  of 
15 mg melox icam compared  with 100 mg dic lofenac 
admin is tered once dai ly in a 6-week, double-bl ind, 
para l le l  group study in pat ients  with osteoarthr i t i s  
of the knee. 
Methods 
STUDY DESIGN 
This randomized,  double-bl ind comparat ive  
study was carr ied out  at  23 centers in Belgium, 
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Denmark, Germany and the Netherlands. The 
study protocol received approval from the appro- 
priate ethics committee(s) in each of the participat- 
ing countries before commencement of the trial. 
All patients gave written informed consent to 
participation i the study. The trial was performed 
in accordance with the Declaration of Helsinki. 
Patients were eligible for inclusion in the trial 
providing they were at least 18 years of age, 
ambulatory, and had a clinically and radiographi- 
cally confirmed iagnosis of osteoarthritis of the 
knee for a period of 3 months. The criteria for 
clinical and radiographical confirmation of osteo- 
arthritis required that movement of the knee by 
extreme flexion and extension elicited pain; X-rays 
in different projections demonstrated at least 
narrowing of the femoropatellar nd/or femorotib- 
ial space and osteophytes and/or subchondral 
sclerosis and/or cysts; and patients had experi- 
enced at least moderate pain in the worst-affected 
knee (i.e., a score of 35 mm or more on a visual 
analog scale (VAS) as assessed by the patient; 
0 mm equals 'no pain', 100 mm equals 'unbearable 
pain') which was judged by the investigator to 
require treatment with an anti-inflammatory 
agent. Patients receiving therapy for concomitant 
diseases were allowed to continue their medication 
(except medication excluded by the protocol) and 
any changes in concomitant therapy were docu- 
mented. Treatment with other NSAIDs and oral or 
intra-articular steroids was not permitted. The 
washout period for pre-treatment with piroxicam 
and tenoxicam was 7 days and at least 3 days for 
other NSAIDs. Treatment with oral or intra-artic- 
ular steroids was not permitted in the 3 months 
before the study. Paracetamol could be used as 
'rescue' analgesic throughout he study at a 
maximum daily dose of 4 g. 
Two hundred and sixty-eight patients were 
enroled in the study. Initially it had been intended, 
to compare two doses of meloxicam with diclofe- 
nac, and at the beginning of the study period 
patients entering the trial were randomized to 
receive 15mg meloxicam, 30mg meloxicam or 
100mg diclofenac, once daily for 6 weeks. 
Meloxicam or matching placebo were given as 
capsules, and SR dictofenac or matching placebo 
as coated tablets. Shortly after the trial began, 
clinical development of the 30 mg dose of meloxi- 
cam was discontinued and treatment was with- 
drawn. These 10 patients were evaluated 
separately. 
All 258 patients receiving 15mg meloxicam 
(N=128) or 100mg diclofenac (N=130) were 
evaluated on an 'intent-to-treat' basis. Baseline 
demographics were similar in the two treatment 
groups (Table I). All patients pretreated with 
NSAIDs underwent a washout period of between 3
and 7 days. 
CLINICAL ASSESSMENTS AND EFFICACY VARIABLES 
Clinical assessments were made at the end of the 
washout period and after 1, 3 and 6 weeks of active 
treatment. The main study endpointwas the worst 
level of pain in the target knee during active 
movement. This was assessed by the p~tient for the 
previous 24 h using a horizontal VAS r~g ing  from 
'no pain' (0 mm) to 'unbearable pain' (100:,ram). The 
secondary study endpoints assessed were as 
follows. 
(1) Worst level of pain in the target knee at rest 
in the previous 24 h assessed by the patient using 
a horizontal VAS as described above. 
(2) Global efficacy as assessed by the patient on 
a horizontal VAS ranging from 'excellent' (0 mm) 
to 'useless') 100 mm) at the end of the study. 
(3) Lequesne Index of Severity for osteoarthritis 
of the knee at the beginning and at the end of the 
study [11]. 
(4) Consumption of paracetamol during the 
washout and treatment periods (assessed at each 
visit). 
(5) Occurrence of withdrawals due to in- 
adequate fficacy. 
(6) Tolerance of study treatment since the last 
visit, assessed by the patient on a horizontal VAS 
ranging from 'excellent' (0 mm) to 'extremely bad' 
(100 mm). 
(7) Global tolerance as assessed by the patient 
on a horizontal VAS ranging from 'excellent' 
(0 mm) to 'extremely bad' (100 mm) at the end of the 
study. 
Table I 
Patient characteristics 
Meloxicam (15 mg) Diclofenac (100 mg) 
No. of patients male/female 19/109 23/107 
Age (years) (mean ± S.D.) 71.5 ± 12.0 71.4 ± 11.6 
Osteoarthritis diagnosis duration (years) 
(mean ± S.D.) 7.6 _+ 6.4 7.3 ± 6.4 
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(8) Occur rence  of w i thdrawals  due to poor  
to lerance.  
(9) Laboratory  invest igat ions  (hematology,  bio- 
chemistry,  urinalysis),  per formed on entry  to the 
study and after  3 and 6 weeks of act ive t reatment .  
Cl in ical ly s igni f icant changes in one or more 
laboratory  parameters  were defined as an adverse 
event. All adverse events  were recorded and 
described. Gast roscop ies  were only per formed at 
the d iscret ion of the t reat ing  phys ic ian in pat ients  
with signs and/or  symptoms which suggested that  
gast roscopy would be meaningful .  
STAT IST ICAL  ANALYS IS  
The dif ferences compared  with basel ine for pa in  
on movement  and pain  at rest  were analyzed by a 
t reatment -center  analys is  of var iance.  The two 
sample t-test was appl ied to global  eff icacy and 
global  to lerance.  The Kruska l -Wa l l i s  test was 
used to test  the inf luence of the t reatment  on the 
changes in Tota l  Index of Sever i ty  of osteoar thr i t i s  
of the knee. Results  are reported as nons igni f icant  
if P> 0.05. The last value carr ied forward 
procedure was used to adjust  for miss ing values. 
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FIG. 1. Pain on movement throughout the study [mean 
(+S.E.) changes from baseline, measured on 100mm 
VAS]. Lower values means less pain: 0 mm= no pain, 
100 mm = unbearable pain. Baseline values were 60.0 mm 
and 59.7 mm in the metoxicam and diclofenac groups, 
respectively. (0)  15 mg meloxicam; ((2)) 100 mg diclofe- 
nac. 
Resu l ts  
EFF ICACY 
The results  with respect  to eff icacy showed a 
t rend in favor  of me lox icam regard ing  pain  on 
movement ,  g lobal  eff icacy and paracetamol  con- 
sumption,  a l though these dif ferences did not  reach  
stat ist ica l  signif icance. The results  for the main  
efficacy endpoint,  pa in  on movement ,  are illus- 
t rated in Fig. 1 ( intent-to-treat  nalysis).  Basel ine 
values of the two t reatment  groups  were compar-  
able, with a mean ( iS .D.)  of  60.0 i 14.5 mm in the 
melox icam group and 59.7 + 13.9mm in the 
dic lofenac group. Both  t reatment  groups were 
character ized by a re lat ive ly - large reduct ion  in 
pain by day 7 and a gradual ,  but  less pronounced,  
fur ther  reduct ion  over  the course of the t reatment  
period. The melox icam t reatment  group showed a 
more pronounced mean improvement  f rom day 
21-42 compared  with diclofenac. 
Table I I  shows the levels of worst  pain at rest  in 
the ta rget  knee throughout  he study. Me lox icam 
and dic lofenac were s imi lar ly  effective in reduc ing 
pain. A pronounced improvement  in pain was seen 
by day 7 in both t reatment  groups. This level of 
pain contro l  was mainta ined,  with only a s l ight 
fur ther  improvement  hroughout  the whole tr ia l  
period. 
Pat ient  assessment  of global  efficacy after  the 
6-week t reatment  per iod indicated a t rend for 
bet ter  global  efficacy of me lox icam (Fig. 2). The 
Tota l  Index of Sever i ty  (0-24 points) for osteo- 
ar thr i t i s  of the knee at study entry  was s imi lar  for 
the two t reatment  groups. After 6 weeks  of 
t reatment  pat ients  in both t reatment  groups 
showed a s imi lar  improvement  in the Tota l  Index 
of Sever i ty  (Table III). Reduct ions  were seen in a l l  
three scores of the Index, pa in  assessment,  
max imum walk ing d istance and rout ine dai ly 
act iv i t ies (Table III). 
Table II 
Worst level of pain in the target knee at rest in the previous 
24 h as assessed by the patient 
Day0 Day 7 Day 21 Day 42 
Meloxicam (15 mg) 
N 128 128 128 128 
Mean 36.0 20.7 17.5 16.2 
S.D. 21.5 19.4 18.9 18.6 
Diclofenac (100 mg) 
N 130 130 130 130 
Mean 39.3 23.2 21.8 20.4 
S.D. 22.6 19.7 20.4 22.0 
VAS, 0 mm = no pain, 100 mm = unbearable pain. 
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FIG. 2. Mean (±S.E.) global efficacy assessed by the 
patient at the end of the study. Lower values means less 
pain: 0 mm = excellent, 100 mm = useless. 
Five of the 128 pat ients  t reated with melox icam 
and three of 130 pat ients  in the dic lofenac 
t reatment  group wi thdrew from t reatment  due to 
lack of efficacy. 
There was no t reatment -paracetamol  inter- 
act ion for any of the eff icacy end points, i.e. 
paracetamol  consumpt ion  had no s ignif icant 
inf luence on the eff icacy results. The mean 
paracetamol  consumpt ion  throughout  he tr ia l  was 
less than  one tablet  (of 500 mg) per day. A decrease 
in paracetamol  consumpt ion  from the washout  
period to the per iod between day 21 and day 42 was 
seen in both groups. However ,  the decrease in 
paracetamol  consumpt ion  was sl ightly greater  in 
the melox icam-treated pat ients  (from 0.5 to 
0.18g/day and from 0.47 to 0.24g/day for the 
melox icam and dic lofenac t reatment  groups, 
respectively).  
SAFETY AND TOLERABIL ITY  
Adverse events were reported in 44 (34.4%) 
pat ients  on 15mg melox icam and 47 (36.2%) 
pat ients  on 100mg diclofenac. The types and 
frequencies of adverse events in the t reatment  
groups are shown in Table  IV. The most  
f requent ly -occurr ing adverse events were dis- 
orders of the GI  system in 21 (16.4%) pat ients  in the 
15rag melox icam t reatment  group and in 34 
(26.2%) pat ients  in the 100 mg diclofenac group. 
The most  f requent  GI  events were dyspepsia (7 vs 
11% incidence in the melox icam and dic lofenac 
t reated  groups, respectively),  nausea  (5 vs 6%), 
abdomina l  pain (3 vs 5%) and d iar rhoea (3 vs 4%) 
One pat ient  who had been t reated with dic lofenac 
for 22 days was hospita l ized due to severe 
abdomina l  pain; endoscopy revealed a gastr ic  
ulcer. None of the pat ients  in the melox icam group 
presented with signs or symptoms suggest ing a 
diagnosis  of GI  ulcers. Therefore,  e~doscopies of 
the GI  t ract  were not per formed in the~ melox icam 
group. 
Card iovascu lar  disorders (3 vs 1% of the t reated 
pat ients  with adverse events in the melox icam and 
dic lofenac group, respectively),  centra l  and~er iph-  
eral  nervous disorders (8 vs 5%) and ~ inary  
system disorders (4 vs 1%) were somewhat  more 
f requent  in the group of pat ients  t reated with 
meloxicam. None of the ur inary  t ract  disorders 
(cystit is and ur inary  t ract  infection) was judged to 
be causal ly  re lated to the study drugs by the 
invest igators .  Sl ight increases of mean serum 
creat in ine  and urea values occurred in both 
t reatment  groups. 
A tota l  of 45 pat ients  were w i thdrawn from the 
study because of adverse events (21 pat ients  and 24 
pat ients  in the melox icam and dic lofenac treat-  
ment  groups, respectively).  
Both agents were well  to lerated throughout  he 
Table III 
Index of severity 
Day 0 Day 42 
Treatment Mean _+ S.D. Mean ± S.D. Difference 
Meloxicam (15 mg) (N= 128) 
Total 
Pain assessment 
Maximum walking distance 
Routine daily activities 
Diclofenac (100 mg) 
Total 
Pain assessment 
Maximum walking distance 
Routine daily activities 
13.9 ± 3.3 
5.7 ± 1.5 
3.0 ± 1.4 
5.2 ± 1.3 
13.4 ± 3.3 
5.6 ± 1.4 
2.9 ± 1.5 
4.9 ± 1.6 
11.0 _ 4.5 -2.9 
4.1 ± 1.9 -1.5 
2.5 _+ 1.5 -0.5 
4.4 ± 1.9 -0.8 
10.6 + 4.8 -2.7 
4.2 _+ 2.1 -1.4 
2.3 ± i.5 -0.6 
4.1 _+ 2.0 -0.8 
Points available: total ((~24), pain assessment (0-8), maximum walking distance (0-6), 
routine daily activities (0-10). 
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Table IV 
Adverse events: frequencies--WHO body system classes (intent-to-treat nalysis) 
Metoxicam (15 mg) Diclofenac (100 mg) 
Adverse events frequency (%) frequency (%) 
Body as a whole--general disorders 
Cardiovascular disorders, general 
Central and peripheral nervous ystem disorders 
GI system disorders 
Heart rate and rhythm disorders 
Liver and biliary system disorders 
Metabolic and nutritional disorders 
Musculoskeletal system disorders 
Myo-, end-, pericardial and valve disorders 
Neoplasms 
Psychiatric disorders 
Respiratory system disorders 
Skin and appendages disorders 
Urinary system disorders 
Vascular (extracardiac) disorders 
Patients without adverse vents, N= 167 
Withdrawals due to adverse vents, N= 45 
Total patients, N= 258 
6 (4.7) 7 (5.4) 
4 (3.1) 1 (0.8) 
10 (7.8) 6 (4.6) 
21 (16.4) 34 (26.2) 
1 (0.8) 1 (0.8) 
1 (0.8) 0 (0.0) 
1 (0:8) 0 (o.o) 
1 (0.8) 1 (0.8) 
1 (0.8) 1 (0.8) 
0 (0.0) 1 (0.8) 
3 (2.3) 1 (0.8) 
3 (2.3) 1 (0.8) 
4 (3.1) 2 (1.5) 
5 (3.9) 1 (0.8) 
1 (o.8) 0.(0.0) 
84 (65.6) 83 (63.8) 
21 (16.4) 24 (18.5) 
128 130 
treatment course as assessed by patients on a VAS 
ranging from 0ram (excellent) to 100mm (ex- 
tremely bad). The global tolerance assessed by the 
patient on the VAS at the end of the 6-week course 
of treatment gave mean (_+S.D.) values of 
13.5 _+ 24.5 mm and 16.5 i 26.5 mm in the meloxi- 
cam and diclofenac groups, respectively. 
Discuss ion  
This trial demonstrates that the efficacy of 
meloxicam in osteoarthrit is compares well with 
that of diclofenac, an established therapy in this 
condit ion.  Pain on walking severely impairs 
mobility and thus qual ity of life of many patients 
with osteoarthritis. Thus it is of importance that 
both treatment groups experienced a reduction in 
pain on movement, with the meloxicam group 
showing a more pronounced pain reduction. 
Meloxicam and diclofenac were similarly effective 
in reducing pain at rest, and the patients' 
assessment of global efficacy indicated a trend in 
favor of meloxicam. The improvements in pain 
scores from baseline to study end (46% on 
movement and 55% at rest) are consistent with 
those seen in other trials of 15 mg meloxicam. For 
example, in a 3-week placebo-controlled trial and 
a 6-week comparative trial vs piroxicam, 15 mg 
meloxicam produced improvements in pain on 
movement of 40 and 47%, respectively, and of 55 
and 49% in pain at rest [12, 13]. 
Additionally, GI adverse events were less 
frequent in patients taking meloxicam (occuring in 
16% of patients compared with 26% for diclofe- 
nac).  This observation accords well with other 
clinical results with meloxicam. A global safety 
analysis of the meloxicam clinical study program 
has shown that meloxicam produces ignificantly 
fewer GI adverse events than the standard 
NSAIDs, diclofenac, piroxicam and naproxen [14]. 
The results in the present study vs 100mg 
diclofenac emphasize the outstanding safety of 
meloxicam, as diclofenac is generally felt to be a 
well-tolerated NSAID. Indeed, in a population 
study of NSAID use, diclofenac was found to have 
one of the lowest incidences of peptic bleeding of 
the drugs tested [10]. Studies in animals have 
shown that the therapeutic ndex of meloxicam, as 
calculated from the dose which produces ulcero- 
genic effects in the rat stomach and the effective 
dose, is higher than that of other widely used 
NSAIDs [15]. 
Both the therapeutic (anti-inflammatory) and GI 
side effects of NSAIDs are brought about by their 
inhibition of prostaglandin biosynthesis via inhi- 
bition of the cyclo-oxygenase (COX) enzyme [16]. 
Meld~icam's improved tolerabil ity profile may be 
explained by the observation that it preferential ly 
inhibits the inducible COX produced in areas of 
inflammation (COX-2), but has little effect of 
physiological COX (COX-l) [6]. 
In conclusion, this trial confirmed the efficacy of 
meloxicam in . the  treatment of patients with 
osteoarthritis. In terms of both efficacy and 
tolerability, meloxicam was shown to be at least 
equivalent to an established treatment, diclofenac 
100 mg. There was a trend in favor of meloxicam in 
terms of eifficacy, part icularly towards the end of 
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the trial. Fewer  GI  adverse events were seen with 
meloxicam. This suggests  that  melox icam is l ikely 
to be a useful  addit ion to the drugs cur rent ly  
avai lab le  for the t reatment  of pat ients  with 
osteoarthr i t is .  
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